专利检索 ap:("INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)" OR "ECOLE NATIONALE VÉTÉRINAIRE DE TOULOUSE" OR "INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT" OR "UNIVERSITÉ TOULOUSE III - PAUL SABATIER") AND inv:"Frank LEZOUALC'H" 第 1 页

1.

发明公开
THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION 审中-公开

公开(公告)号：US20230226027A1

公开(公告)日：2023-07-20

申请号：US18001147

申请日：2021-06-11

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ECOLE NATIONALE VÉTÉRINAIRE DE TOULOUSE , INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT , UNIVERSITÉ TOULOUSE III - PAUL SABATIER

发明人： Frank LEZOUALC'H , Romain VOLMER , Charlotte FORET-LUCAS , Thomas FIGUEROA

IPC分类号： A61K31/4365 , A61P31/14

CPC分类号： A61K31/4365 , A61P31/14

摘要： Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The emergence of a new beta-coronavirus SARS-CoV-2 has led to a major health-related crisis associated with a significant mortality in intensive care units, due to the pulmonary complications of COVID-19. The inventors showed that an inhibitor of EPAC1 (i.e. AM-001) is suitable for inhibiting replication of coronavirus and thus would be suitable for the treatment of infections mediated by said type of virus.

2.

发明申请
EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS 有权

公开(公告)号：US20230030517A1

公开(公告)日：2023-02-02

申请号：US17783928

申请日：2020-12-11

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Paul Sabatier Toulouse III , Icahn School of Medicine at Mount Sinai

发明人： Malik BISSERIER , Frank LEZOUALC'H , Lahouaria HADRI

IPC分类号： A61K31/4365 , A61K31/47 , A61P11/00

摘要： The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no cure for IFF. The inventors showed that EPAC1 inhibitors, in particular CE3F4 and AM-001, represent a promising therapeutic strategy for treating patients with pulmonary fibrosis. The present invention thus relates to an EPAC1 inhibitor for use in the treatment and/or prevention of idiopathic pulmonary fibrosis.

3.

发明申请
TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS EPAC1 INHIBITORS FOR THE TREATMENT OF MYOCARDIAL INFARCTION INJURY 审中-公开

公开(公告)号：US20170079970A1

公开(公告)日：2017-03-23

申请号：US15126312

申请日：2015-03-20

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , UNIVERSITÉ PAUL SABATIER TOULOUSE III

发明人： Frank LEZOUALC'H , Pierre SICARD , Malik BISSERIER

IPC分类号： A61K31/47 , A61K45/06

CPC分类号： A61K31/47 , A61K45/06 , A61K2300/00

摘要： The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a method for providing cardioprotection in a subject who experienced a myocardial infarction comprising administering the subject with a therapeutically effective amount of at least one EPAC1 inhibitor.